<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04123067</url>
  </required_header>
  <id_info>
    <org_study_id>00011042</org_study_id>
    <nct_id>NCT04123067</nct_id>
  </id_info>
  <brief_title>Pioglitazone Treatment for Hyperglycemic Acute Ischemic Stroke</brief_title>
  <official_title>Pioglitazone Treatment for Hyperglycemic Acute Ischemic Stroke: Effects on the Stress-Immune Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Advancing Translational Science (NCATS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study objective is to determine whether Pioglitazone (PGZ) can improve clinical outcomes in
      hyperglycemic acute ischemic stroke (IS). The rationale for the proposed research is to
      develop an acute intervention that can improve neurological recovery and decrease mortality
      and morbidity in high-risk diabetic stroke patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 22, 2020</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical outcomes</measure>
    <time_frame>90 days post stroke</time_frame>
    <description>NIH-Stroke scale (0-42) to assess neurological function with 0 being no deficits and 42 being the worst score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Outcome</measure>
    <time_frame>90 days post stroke</time_frame>
    <description>modified Rankin Scale (0-6) to assess neurological function with a score of 0 for no neurological deficits and a maximum of 6 for an expired patient</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of markers of neutrophil activation and function</measure>
    <time_frame>24 hours, 48 hours, and 90 days post-stroke</time_frame>
    <description>measured in blood by flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of stress response markers including cortisol, norepinephrine and epinephrine</measure>
    <time_frame>24 hours, 48 hours, and 90 days poststroke</time_frame>
    <description>measured in blood</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Stroke, Acute</condition>
  <condition>Hyperglycemia</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Pioglitazone treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral administration of 45mg Pioglitazone daily for three subsequent days, initiated within 12h of stroke symptom onset</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral administration of placebo daily for three subsequent days, initiated within 12h of stroke symptom onset</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone 45 mg</intervention_name>
    <description>45mg Pioglitazone daily for three subsequent days, initiated within 12h of stroke symptom onset</description>
    <arm_group_label>Pioglitazone treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>placebo daily for three subsequent days, initiated within 12h of stroke symptom onset</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Stroke Patients ages 21 and over

          2. Blood sugar ≥ 150 mg/dl

          3. Study drug treatment should be initiated within 12 hours after time of symptom onset,
             if known, or the time last known normal (if time to symptom onset is unknown)

          4. MRI or CT proven ischemic stroke

          5. Initial NIH SS of ≥ 2

          6. Willing and able to provide consent

        Exclusion Criteria:

          1. Known hypersensitivity to PGZ.

          2. Infection at the time of presentation as defined by body temperature &gt; 38 degrees C ,
             pneumonia evident on chest X-ray, urinary tract infection (positive tests for
             nitrites, leukocyte esterase, and bacteria on urine analysis), other acute infection
             per history or current use of antibiotic or antiviral treatment.

          3. Active malignancy and / or autoimmune disease requiring treatment.

          4. Use of immunomodulatory drugs or chemotherapy.

          5. History of stroke or brain injury within the last 90 days prior to presentation.

          6. Acute illness within the last 30 days which could have affected the white blood cell
             count.

          7. Known history of clinically significant hypoglycemia.

          8. Patients already taking PGZ.

          9. Active liver disease (ALT and /or AST 2.5 times the upper limit of normal, total
             bilirubin &gt; 1.2 mg/dl).

         10. Acute decompensated heart failure, and/or admission for an acute coronary syndrome,
             myocardial infarction (MI), cardiac arrest, coronary artery surgery within the past 3
             months and patients with New York Heart association Class III and IV heart failure.

         11. History of bladder cancer

         12. Pregnant and nursing women.

         13. Currently incarcerated patients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kerstin Bettermann, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kusum Sinha, coordinator</last_name>
    <phone>717-531</phone>
    <phone_ext>1803</phone_ext>
    <email>ksinha@pennstatehealth.psu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Deborah Hoffman, study nurse</last_name>
    <phone>717-531-0003</phone>
    <phone_ext>283063</phone_ext>
    <email>dhoffman1@pennstatehealth.psu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Penn State College of Medicine</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 8, 2019</study_first_submitted>
  <study_first_submitted_qc>October 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2019</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Kerstin Bettermann</investigator_full_name>
    <investigator_title>Associate Professor of Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

